SENTI-202 CAR NK cell therapy

CAR NK cell therapy targeting CD33 and FLT3 · Senti Biosciences

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SENTI-202 CAR NK cell therapy, covering 2026-02-12 to 2026-02-12. Get the full timeline:

Most recent: Clinical Trial Update: SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS [Phase 1]

See pricing